Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs

For biosimilar drug development programs, it is essential to demonstrate that there are no clinically significant differences between the proposed biosimilar therapeutic (biosimilar) and its reference product (originator). Based on a stepwise comprehensive comparability exercise, the biosimilar must...

Full description

Saved in:

Bibliographic Details
Published in:	The AAPS journal Vol. 22; no. 1; p. 7
Main Authors:	Civoli, Francesca, Kasinath, Aparna, Cai, Xiao-Yan, Wadhwa, Meenu, Exley, Andrew, Oldfield, Philip, Alvandkouhi, Safa, Schaffar, Gregor, Chappell, John, Bowsher, Ronald, Devanarayan, Viswanath, Marini, Joseph, Rebarchak, Shannon, Anderson, Michael, Koppenburg, Vera, Lester, Todd
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 01-01-2020
Subjects:	Biochemistry Biomedical and Life Sciences Biomedicine Biosimilar Pharmaceuticals Biotechnology Immunologic Techniques Pharmacology/Toxicology Pharmacy Validation Studies as Topic White Paper Immunogenicity Anti-drug antibodies ADA Biosimilar
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	For biosimilar drug development programs, it is essential to demonstrate that there are no clinically significant differences between the proposed biosimilar therapeutic (biosimilar) and its reference product (originator). Based on a stepwise comprehensive comparability exercise, the biosimilar must demonstrate similarity to the originator in physicochemical characteristics, biological activity, pharmacokinetics, efficacy, and safety, including immunogenicity. The goal of the immunogenicity assessment is to evaluate potential differences between the proposed biosimilar product and the originator product in the incidence and severity of human immune responses. Establishing that there are no clinically meaningful differences in the immune response between the products is a key element in the demonstration of biosimilarity. An issue of practical, regulatory, and financial importance is to establish whether a two-assay (based on the biosimilar and originator respectively) or a one-assay approach (based on the biosimilar) is optimal for the comparative immunogenicity assessment. This paper recommends the use of a single, biosimilar-based assay for assessing immunogenic similarity in support of biosimilar drug development. The development and validation of an ADA assay used for a biosimilar program should include all the assessments recommended for an innovator program (10–16, 29). In addition, specific parameters also need to be evaluated, to gain confidence that the assay can detect antibodies against both the biosimilar and the originator. Specifically, the biosimilar and the originator should be compared in antigenic equivalence, to assess the ability of the biosimilar and the originator to bind in a similar manner to the positive control(s), as well as in the confirmatory assay and drug tolerance experiments. Practical guidance for the development and validation of anti-drug antibody (ADA) assays to assess immunogenicity of a biosimilar in comparison to the originator, using the one-assay approach, are described herein.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1550-7416 1550-7416
DOI:	10.1208/s12248-019-0386-y